Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Revolution Medicines is heading into its November 5 earnings date with the sharpest short-building in months running directly against an analyst community that has barely flinched.
The short-interest move is the standout change since the last note filed on October 7. Positions have climbed 20.6% over the past week alone to 6.1% of the free float, up from roughly 5% a month ago and the highest level in the 30-day look-back window. The jump between October 7 and October 9 is the most visible step change, with shares short rising from around 9.7 million to 11.7 million in a single session. Cost to borrow has followed, up 23% on the week to 0.63%, a notable direction shift even if the absolute rate remains low. What the lending market is not showing is constraint: availability is extremely loose, running at nearly 4,000% of short interest, meaning for every share already borrowed there are roughly 40 more available in the pool. Bears can build positions without friction. The short score, which held in the low 40s for most of September, has moved to 46.1, its highest reading of the past two weeks. The setup is one of rising conviction on the short side, not a squeeze-risk story.
Options positioning is not amplifying that caution. The put/call ratio is 0.83, slightly below its 20-day average of 0.85 and more than half a standard deviation softer than the mean. The 52-week range runs from 0.16 to 1.80, which puts today's reading squarely in the neutral zone. Options traders are not adding to the defensive tilt that short sellers appear to be signalling.
The analyst picture has barely shifted from the note published a week ago, but it remains the clearest bullish counterweight to the positioning data. RBC Capital raised its target a dollar to $260 on October 14, and raised again on October 8 from $251 to $259, continuing the pattern of incremental upward revisions rather than any abrupt directional change. The consensus mean target is $259.18, implying roughly 37% upside from the $188.44 close, a gap that has widened as the stock has drifted lower over the past month. The analyst recommendation divergence factor scores at the 97th percentile, meaning the Street is more aligned behind this name than almost any other in the ORTEX universe. The bull case centres on daraxonrasib's approval in metastatic pancreatic cancer, a 7.2-month median PFS against 3.6 months for comparator, more than 2,000 early-access programme patients as a commercial proof point, and the breadth of the pan-RAS platform beyond the initial indication. The bear case focuses on execution risk in a competitive KRAS space, ongoing cash burn, and approval probabilities for pipeline assets that still range from 50% to 75%.
Institutional ownership is broadly supportive. BlackRock added 2.5 million shares in the quarter to September 30, lifting its stake to 6.4% of shares outstanding. Fidelity (FMR LLC) added 3.5 million shares in the same period, reaching 5.6%. Capital Research initiated a position of just over 4 million shares also in the September quarter. The insider picture is less informative: all recent trades on file are open-market sales under pre-arranged 10b5-1 plans, the most recent involving the Chief Development Officer selling roughly 6,000 shares on September 29 at around $200. Planned sales carry far less signal than discretionary ones, and the net insider figure for the 90 days to September 29 reflects these scheduled disposals rather than any fresh conviction.
Correlated peers had a rough week. PRAX fell 13.1% on the week and SNDX dropped 19.7%, a sharper move than RVMD's 5.7% decline. SLS bucked the sector trend, gaining 9.4%. The broader peer group weakness gives some cover to the RVMD pullback, but the scale of short-building in RVMD specifically suggests something more than a sector-wide rotation.
The two items to watch into November 5 are whether short interest continues to build at this week's pace, and whether any of the Street's bullish targets start to move in response to early commercial data points from the daraxonrasib launch.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
